跳至主要内容
临床试验/NCT06620627
NCT06620627招募中不适用

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection (PROCEED-CRC)

Natera, Inc.1 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2024年1月26日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Natera, Inc.
入组人数
5,000
试验地点
1
主要终点
Primary Objective

研究概览

简要总结

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

详细描述

Participants who meet study inclusion criteria will be invited to enroll in the study and will provide written consent prior to study procedures. Participants will provide blood samples and will be required to have a colonoscopy performed within 120 days of their blood draw. No test results from the blood collection will be provided to participants or clinicians.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 40 years of age or older at time of consent.
  • Planning or intending to undergo asymptomatic screening colonoscopy.
  • Able to tolerate venipuncture for research draw(s).
  • Able and willing to provide blood samples within the 120 days prior to a colonoscopy procedure.
  • Willing and able to comply with the study visit schedule and study requirements.
  • Signed informed consent(s) must be obtained prior to participation in the study

排除标准

  • Any prior history of any kind of malignancy (exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
  • Had a complete colonoscopy with adequate bowel preparation in the previous nine (9) years.
  • Undergoing diagnostic colonoscopy for investigation of symptoms such as unexplained and long-lasting diarrhea, overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
  • Undergone colorectal cancer screening within the associated recommended intervals
  • FOBT/FIT within the previous 12 months
  • FIT-DNA test within the previous 36 months
  • Blood-based CRC screening test within the previous 36 months
  • Computed tomography colonography CTC within the previous 5 years
  • Flexible sigmoidoscopy within the previous 5 years
  • Precancerous findings on most recent colonoscopy. This does not include benign, and/or hyperplastic polyps of any size (Note: Tissue biopsies that result in no histopathology findings are acceptable)
  • Had a prior colorectal resection for any reason other than sigmoid diverticular disease
  • Diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
  • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohns disease
  • Familial adenomatous polyposis (also referred to as FAP, including attenuated FAP)
  • Hereditary non-polyposis colorectal cancer syndrome (also referred to as HNPCC or Lynch Syndrome)
  • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardners Syndrome, Turcots (or Crails) Syndrome, Cowdens Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis

结局指标

主要结局

Primary Objective

时间窗: 12 months

To collect samples for the research use and the development of a blood-based colorectal cancer screening test in the average risk population

次要结局

未报告次要终点

研究者

发起方
Natera, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验